Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705187 | 0.89 | KCNH2 (0.53) | KCNH2ALDH1A1KMOPOLBMAPT | |
| SCHEMBL707698 | 0.86 | KCNH2 (0.46) | KCNH2ALDH1A1KMOPOLBMAPT | |
| SCHEMBL706951 | 0.84 | KCNH2 (0.43) | KCNH2ALDH1A1KMOPOLBMAPT | |
| SCHEMBL706952 | 0.84 | KCNH2 (0.43) | KCNH2ALDH1A1KMOPOLBMAPT | |
| SCHEMBL923797 | 0.81 | KCNH2 (0.53) | KCNH2KMOCHRM1TSHRHTT | |
| SCHEMBL707963 | 0.80 | KCNH2 (0.46) | KCNH2ALDH1A1KMOPOLBMAPT | |
| Trifluoroacetic Acid SCHEMBL705792 | 0.80 | KCNH2 (0.43) | KCNH2ALDH1A1KMOPOLBMAPT | |
| SCHEMBL705942 | 0.79 | KCNH2 (0.49) | KCNH2ALDH1A1KMOPOLBMAPT | |
| SCHEMBL709161 | 0.77 | KCNH2 (0.51) | KCNH2ALDH1A1KMOPOLBCHRM1 | |
| SCHEMBL705652 | 0.76 | TSHR (0.53) | ALDH1A1POLBMAPTCHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885ALDH1A1 2130/4885KMO 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.